Last reviewed · How we verify
Viaskin Peanut
At a glance
| Generic name | Viaskin Peanut |
|---|---|
| Also known as | DBV712 |
| Sponsor | DBV Technologies |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) (PHASE3)
- Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age (PHASE3)
- Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children
- Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy (PHASE3)
- Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children (PHASE3)
- Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age (PHASE3)
- Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children (PHASE2)
- Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Viaskin Peanut CI brief — competitive landscape report
- Viaskin Peanut updates RSS · CI watch RSS
- DBV Technologies portfolio CI